1 / 13

FDA ADVISORY COMMITTEES

FDA ADVISORY COMMITTEES. Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA. FDA/Industry workshop Bethesda, MD September 19, 2003. CDER Cardio-Renal Drugs AntiInfective Drugs Antiviral Drugs Oncologic Drugs CBER

zamora
Download Presentation

FDA ADVISORY COMMITTEES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FDA ADVISORY COMMITTEES Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA FDA/Industry workshop Bethesda, MD September 19, 2003

  2. CDER Cardio-Renal Drugs AntiInfective Drugs Antiviral Drugs Oncologic Drugs CBER Blood & Blood Products Vaccines CVM Veterinary Meds CDRH Circulatory System Devices Dental Devices Radiologic Devices CFSAN Food Advisory NCTR Ranch Hand Range of Advisory Committees

  3. FACA • Federal Advisory Committee Act Public Law 92-463 • Independent advice on scientific issues • Enhance, compliment, speed decision-making • Provide forum for public input (advanced notice, public meetings) • http://www.gsa.gov/Portal/browse/channel.jsp?channelId=-13689

  4. FACA • Scientific – Not Policy • Advisory Only • One hour for public comment • Have Background material fr all sides 18 days prior to mtg (also webposted) • Limitations on Last-Minute Material

  5. INDEPENDENCE • Appointed by Commissioner • Fixed Terms • Screened for COI/Bias • Large Role Played by Chair

  6. Standing mbrs Scientific/Tech experts Statistician Consumer rep Industry rep Other invitees Patient rep Disease/condition experts Occasional Senators COMPOSITION

  7. Pre-Meeting IAs • Generally Limited – Discussion of Issues must be in public • Factual questions possible, but Exec Sec must be involved

  8. General Public FDA Reviewer Executive Secretary Committee Member Industry

  9. 8:00 am 8:15 8:30 10:00 10:15 11:45 1:00 pm 2:00 4:30 Administrative remarks FDA Introduction Sponsor’s Presentation Break FDA’s Presentation Lunch Open Public Hearing Committee Disc’n & Vote Adjourn TYPICAL AGENDA

  10. Questions to ACs • Were studies adequate to evaluate product effect? • Was population studied appropriate? • Is it appropriate to pool data? • Optimal correction methodology for QT correction? • Add’l pt safety monitoring advised? • If licensed, should the label describe any limitations in generalizing to certain subgroups?

  11. Issues for ACs • Discuss trial designs, incl f/up dur’n • Endpoints, esp surrogates • Measurement/quant’n (e.g. QT interval & mult correction meths) • Phase IV commitments • 1st year safety reviews of ped experience mandated by Best Pharmaceuticals for Children Act • Generalizability of results

  12. Perogative • ACs can reword or answer the question they wish had been asked • ACs often answer questions that were not asked, offering advice on future considerations • ACs often ask for more information, more data (e.g. cross-resistance), more studies (e.g. Phase IV)

  13. Statistician’s Responsibility • Know their subject • Know the process COMMUNICATE

More Related